Proteomic analyses of different human tumour-derived chaperone-rich cell lysate (CRCL) anti-cancer vaccines reveal antigen content and strong similarities amongst the vaccines along with a basis for CRCL's unique structure: CRCL vaccine proteome leads to unique structure

International Journal of Hyperthermia

Volumn 29, Issue 6, 2013, Pages 520-527

  Mayer Sonnenfeld, Tehila ^a   Har Noy, Michael ^a   Lillehei, Kevin O ^b   Graner, Michael W ^b  

^a Immunovative Therapies Ltd   (Israel)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Chaperone rich cell lysate; Heat shock proteins; Proteomics

Indexed keywords

CANCER VACCINE; CHAPERONE RICH CELL LYSATE CANCER VACCINE; HEAT SHOCK PROTEIN; PROTEINASE; PROTEOME; UNCLASSIFIED DRUG;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; ARTICLE; CELL LYSATE; COLORECTAL CANCER; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MASS SPECTROMETRY; MOLECULAR SIZE; MOUSE; NONHUMAN; ONTOGENY; OVARY CANCER; PROTEIN CONTENT; PROTEIN DETERMINATION; STRUCTURAL PROTEOMICS; TRANSMISSION ELECTRON MICROSCOPY;

AGED; ANTIGENS, NEOPLASM; CANCER VACCINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; NEOPLASMS; PROTEOME; PROTEOMICS;

EID: 84882768927     PISSN: 02656736     EISSN: 14645157     Source Type: Journal    
DOI: 10.3109/02656736.2013.796529     Document Type: Article

References (53)

1. Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, et al. An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: A multicentre, open-label, randomised phase III trial. Lancet 2008; 372:145-54
2. Testori A, Richards J, Whitman E, Mann GB, Lutzky J, Camacho L, et al. Phase III comparison of vitespen, an autologous tumorderived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: The C-100-21 Study Group. J Clin Oncol 2008;26:955-62 (Pubitemid 351398090)
3. Itoh K, Yamada A, Mine T, Noguchi M. Recent advances in cancer vaccines: An overview. Jpn J Clin Oncol 2009;39:73-80
4. Torigoe T, Tamura Y, Sato N. Heat shock proteins and immunity: Application of hyperthermia for immunomodulation. Int J Hyperthermia 2009;25:610-16
5. Calderwood SK, Theriault JR, Gong J. Message in a bottle: Role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur J Immunol 2005;35:2518-27 (Pubitemid 41404034)
6. Feng H, Zeng Y, Graner MW, Likhacheva A, Katsanis E. Exogenous stress proteins enhance the immunogenicity of apoptotic tumor cells and stimulate antitumor immunity. Blood 2003;101: 245-52 (Pubitemid 36025914)
7. Lammert E, Arnold D, Nijenhuis M, Momburg F, Hämmerling GJ, Brunner J, et al. The endoplasmic reticulum-resident stress protein gp96 binds peptides translocated by TAP. Eur J Immunol 1997;27: 923-7 (Pubitemid 27153662)
8. Arnold D, Faath S, Rammensee H, Schild H. Cross-priming of minor histocompatibility antigen-specific cytotoxic T cells upon immunization with the heat shock protein gp96. J Exp Med 1995; 182:885-9
9. Ishii T, Udono H, Yamano T, Ohta H, Uenaka A, Ono T, et al. Isolation of MHC class I-restricted tumor antigen peptide and its precursors associated with heat shock proteins Hsp70, Hsp90, and gp96. J Immunol 1999;162:1303-09 (Pubitemid 29306999)
10. Graner MW, Romanoski A, Katsanis E. The 'peptidome' of tumourderived chaperone-rich cell lysate anti-cancer vaccines reveals potential tumour antigens that stimulate tumour immunity. Int J Hyperthermia, in press
11. Oura J, Tamura Y, Kamiguchi K, Kutomi G, Sahara H, Torigoe T, et al. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells. Int Immunol 2011;23:223-37
12. Wang XY, Sun X, Chen X, Facciponte J, Repasky E, Kane J, et al. Superior antitumor response induced by large stress protein chaperoned protein antigen compared with peptide antigen. J Immunol 2010;184:6309-19
13. Graner M, Raymond A, Akporiaye E, Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent antitumor vaccines. Cancer Immunol Immunother 2000;49:476-84
14. GranerMW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperonerich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother 2003;52:226-34 (Pubitemid 36535282)
15. Bleifuss E, Bendz H, Sirch B, Thompson S, Brandl A, Milani V, et al. Differential capacity of chaperone-rich lysates in crosspresenting human endogenous and exogenous melanoma differentiation antigens. Int J Hyperthermia 2008;24:623-37
16. Epple LM, Bemis LT, Cavanaugh RP, Skope A, Mayer-Sonnenfeld T, Frank C, et al. Prolonged remission of advanced bronchoalveolar adenocarcinoma in a dog treated with autologous, tumour-derived chaperone-rich cell lysate (CRCL) vaccine. Int J Hyperthermia, in press
17. Rosenfeld J, Capdevielle J, Guillemot JC, Ferrara P. In-gel digestion of proteins for internal sequence analysis after one-or two-dimensional gel electrophoresis. Anal Biochem 1992;203: 173-9
18. Wilm M, Mann M. Analytical properties of the nanoelectrospray ion source. Anal Chem 1996;68:1-8
19. Sigler PB, Xu Z, Rye HS, Burston SG, Fenton WA, Horwich AL. Structure and function in GroEL-mediated protein folding. Annu Rev Biochem 1998;67:581-608 (Pubitemid 28411139)
20. Linderoth NA, Simon MN, Rodionova NA, Cadene M, Laws WR, Chait BT, et al. Biophysical analysis of the endoplasmic reticulumresident chaperone/heat shock protein gp96/GRP94 and its complex with peptide antigen. Biochemistry 2001;40:1483-95 (Pubitemid 32142910)
21. Buonaguro L, Tagliamonte M, Tornesello ML, Buonaguro FM. Developments in virus-like particle-based vaccines for infectious diseases and cancer. Expert Rev Vaccines 2011;10:1569-83
22. Moser C, Amacker M, Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011;10: 437-46
23. Solbrig CM, Saucier-Sawyer JK, Cody V, Saltzman WM, Hanlon DJ. Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells. Mol Pharm 2007; 4:47-57
24. Morein BB. Iscoms. Vet Microbiol 1990;23:79-84
25. Gamvrellis A, Leong D, Hanley JC, Xiang SD, Mottram P, Plebanski M. Vaccines that facilitate antigen entry into dendritic cells. Immunol Cell Biol 2004;82:506-16 (Pubitemid 39421060)
26. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, et al. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol 2007;148: 136-45 (Pubitemid 46364991)
27. Kislin KL, Marron MT, Li G, Graner MW, Katsanis E. Chaperonerich cell lysate embedded with BCR-ABL peptide demonstrates enhanced anti-tumor activity against a murine BCR-ABL positive leukemia. FASEB J 2007;21:2173-84 (Pubitemid 47026452)
28. Binder RJ, Kelly JB III, Vatner RE, Srivastava PK. Specific immunogenicity of heat shock protein gp96 derives from chaperoned antigenic peptides and not from contaminating proteins. J Immunol 2007;179:7254-61
29. Srivastava PK, DeLeo AB, Old LJ. Tumor rejection antigens of chemically induced sarcomas of inbred mice. Proc Natl Acad Sci USA 1986;83:3407-11 (Pubitemid 16043046)
30. Blachere NE, Li Z, Chandawarkar RY, Suto R, Jaikaria NS, Basu S, et al. Heat shock protein-peptide complexes, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med 1997;186:1315-22 (Pubitemid 27469027)
31. Vogen S, Gidalevitz T, Biswas C, Simen BB, Stein E, Gulmen F, et al. Radicicol-sensitive peptide binding to the N-terminal portion of GRP94. J Biol Chem 2002;277:40742-50 (Pubitemid 35215658)
32. Wang L, He S, Tu Y, Ji P, Zong J, Zhang J, et al. Elevated expression of chloride intracellular channel 1 is correlated with poor prognosis in human gliomas. J Exp Clin Cancer Res 2012; 31:44
33. Petrova DT, Asif AR, Armstrong VW, Dimova I, Toshev S, Yaramov N, et al. Expression of chloride intracellular channel protein 1 (CLIC1) and tumor protein D52 (TPD52) as potential biomarkers for colorectal cancer. Clin Biochem 2008;41:1224-136
34. Fotiou K, Vaiopoulos G, Lilakos K, Giannopoulos A, Mandalenaki K, Marinos G, et al. Serum ceruloplasmin as a marker in prostate cancer. Minerva Urol Nefrol 2007;59:407-11 (Pubitemid 350247724)
35. Nayak SB, Bhat VR, Mayya SS. Serum copper, ceruloplasmin and thiobarbituric acid reactive substance status in patients with ovarian cancer. Indian J Physiol Pharmacol 2004;48:486-8 (Pubitemid 39390015)
36. Stella Tsai CS, Chen HC, Tung JN, Tsou SS, Tsao TY, Liao CF, et al. Serum cellular apoptosis susceptibility protein is a potential prognostic marker for metastatic colorectal cancer. Am J Pathol 2010;176:1619-28
37. Tung MC, Tsai CS, Tung JN, Tsao TY, Chen HC, Yeh KT, et al. Higher prevalence of secretory CSE1L/CAS in sera of patients with metastatic cancer. Cancer Epidemiol Biomarkers Prev 2009;18: 1570-7
38. Chakraborty S, Nagashri MN, Mohiyuddin SM, Gopinath KS, Kumar A. Gene expression profiling of oral squamous cell carcinoma by differential display rt-PCR and identification of tumor biomarkers. Indian J Surg Oncol 2010;1:284-93
39. Krol M, Polanska J, Pawlowski KM, Turowski P, Skierski J, Majewska A, et al. Transcriptomic signature of cell lines isolated from canine mammary adenocarcinoma metastases to lungs. J Appl Genet 2010;51:37-50
40. Wang Y, Kuramitsu Y, Ueno T, Suzuki N, Yoshino S, Iizuka N, et al. Glyoxalase I (GLO1) is up-regulated in pancreatic cancerous tissues compared with related non-cancerous tissues. Anticancer Res 2012;32:3219-22
41. Fonseca-Sanchez MA, Rodriguez Cuevas S, Mendoza-Hernandez G, Bautista-Piña V, Arechaga-Ocampo E, Hidalgo-Miranda A, et al. Breast cancer proteomics reveals a positive correlation between glyoxalase 1 expression and high tumor grade. Int J Oncol 2012;41: 670-80
42. Tsujimoto Y, Tomita Y, Hoshida Y, Toyosawa S, Inohara H, Kishino M, et al. Elevated expression of valosin-containing protein (p97) is associated with poor prognosis of prostate cancer. Clin Cancer Res 2004;10:3007-12 (Pubitemid 38619676)
43. Yamamoto S, Tomita Y, Nakamori S, Hoshida Y, Iizuka N, Okami J, et al. Valosin-containing protein (p97) and Ki-67expression is a useful marker in detecting malignant behavior of pancreatic endocrine neoplasms. Oncology 2004;66:468-75 (Pubitemid 39370238)
44. Hamrita B, Chahed K, Kabbage M, Guillier CL, Trimeche M, Chaïeb A, et al. Identification of tumor antigens that elicit a humoral immune response in breast cancer patients' sera by serological proteome analysis (SERPA). Clin Chim Acta 2008;393: 95-102
45. Mojtahedi Z, Safaei A, Yousefi Z, Ghaderi A. Immunoproteomics of HER2-positive and HER2-negative breast cancer patients with positive lymph nodes. OMICS 2011;15:409-18
46. Bunger S, Haug U, Kelly M, Posorski N, Klempt-Giessing K, Cartwright A, et al. A novel multiplex-protein array for serum diagnostics of colon cancer: A case-control study. BMC Cancer 2012;12:393
47. Hao J, Wang K, Yue Y, Tian T, Xu A, Xiao X, et al. Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells. Mol Cell Biochem 2012; 359:323-32
48. Cross SS, Hamdy FC, Deloulme JC, Rehman I. Expression of S100 proteins in normal human tissues and common cancers using tissue microarrays: S100A6, S100A8, S100A9 and S100A11 are all overexpressed in common cancers. Histopathology 2005;46: 256-69 (Pubitemid 40343172)
49. Wei BR, Hoover SB, Ross MM, Zhou W, Meani F, Edwards JB, et al. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS One 2009;4:e7670
50. Okada H, Attanucci J, Giezeman-Smits KM, Brissette-Storkus C, Fellows WK, Gambotto A, et al. Immunization with an antigen identified by cytokine tumor vaccine-assisted SEREX (CAS) suppressed growth of the rat 9L glioma in vivo. Cancer Res 2001;61:2625-31 (Pubitemid 32685848)
51. Shi YY, Wang HC, Yin YH, Sun WS, Li Y, Zhang CQ, et al. Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 2005;92:929-34 (Pubitemid 40462641)
52. Unwin RD, Harnden P, Pappin D, Rahman D, Whelan P, Craven RA, et al. Serological and proteomic evaluation of antibody responses in the identification of tumor antigens in renal cell carcinoma. Proteomics 2003;3:45-55 (Pubitemid 36151067)
53. Slager EH, Honders MW, van der Meijden ED, van Luxemburg-Heijs SA, Kloosterboer FM, Kester MG, et al. Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer. Blood 2006; 107:4954-60 (Pubitemid 43882650)